Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. by Ishikawa, Yuki et al.
Title
Etanercept-induced anti-Jo-1-antibody-positive polymyositis in
a patient with rheumatoid arthritis: a case report and review of
the literature.
Author(s)
Ishikawa, Yuki; Yukawa, Naoichiro; Ohmura, Koichiro;
Ho ono, Yuji; Imura, Yoshitaka; Kawabata, Daisuke; Nojima,
Takaki; Fujii, Takao; Usui, Takashi; Mimori, Tsuneyo
CitationClinical rheumatology (2010), 29(5): 563-566
Issue Date2010-05
URL http://hdl.handle.net/2433/120949





Case [Reference number] Patient 1[11] Patient 2[12] Patient 3[13] Patient 4[14] Present case 
Age(yrs) & Sex 44 female 52 female 52 female 57 female 58 female 
RF/CCP -/- +/ND※1 +/ND +/ND +(724.7)/+（> 100） 
 Duration from RA until anti-TNF 
therapy(Tx.) initiation (yrs) 
1 20 33 26 2 
Previous Tx. for RA HCQ※2, MTX※3 MTX MTX All available DMARDs BUC※4, TAC※5 
Anti-TNF therapy Etanercept Infliximab Infliximab Etanercept Etanercept 
PM/DM onset from anti-TNF Tx. 
initiation 
6 months 6 months 9 months 6 wks after re-treatment 2 months 
Maximum CK※6 (IU/L) 11,593 > 12,000 3,388 1,067 1,538 
pre FANA - 1:320, pattern unknown 1:640, Ho.※7/Spe.※8 1:160 (1999) 1:320, Ho./Nuc.※9 
FANA 1:640, Spe. 1:320, pattern unknown 1:640, Ho./Spe. 1:2560 (2003) 1:320, Ho./Nucl 
Pre※10 anti-dsDNA antibody ND - - ND - 
Anti-dsDNA antibody ND 1:20  IgM (131U/mL) ND - (IgG 11 U/mL) 
Pre Anti-Jo-1 antibody ND + + ( > 500 U/mL) (ELISA) ND 206.9 
Anti-Jo-1 antibody + + + (> 500 U/mL) (ELISA) ND 239 






Size variation, inflammatory 
infiltrates 
Necrotizing myositis 
Mild inflammtory infiltrates 
and necrosis 
Diagnosis Dermatomyositis Polymyositis Polymyositis Polymyositis Polymyositis 
Course & types of ILD Improved; NSIP※11 ? Improved; UIP※12 ? Improved; NSIP ? ARDS developed, due to PCP※13 ? Improved; NSIP or BOOP※14 
Tx. for PM/DM※15 
High-dose PSL※16 plus AZP※
17 150 mg & MTX 10 mg/wk 
MP※18 pulse 1.0 g plus PSL 
1mg/kg 
PSL 30 mg plus TAC 3 mg 
High-dose PSL plus IVCY※19 (500 
mg/m2) 
PSL 1mg/kg plus MP pulse 
0.5 g 
Outcome of myositis Marked improvement Marked improvement Marked improvement Marked improvement Marked improvement 
※1 ND Not done or Not described ＊2 HCQ ＊3 MTX methotrexate hydroxychloropuine ＊4 BUC bucillamine ＊5 TAC tacrolimus ＊6 CPK cleatinine phosphokinase ＊7 Ho. Homogenous pattern ＊8 Spe. Speckled pattern ＊9 Nuc. 
Nucleolar pattern ＊10 pre value before initiation of anti-TNF ＊11 NSIP non-specific interstitial pneumonia ＊12 UIP unusual interstitial pneumonia ＊13 PCP pneumocystis pneumonia ＊14 BOOP bronchiolitis obliterans with 
organizing pneumonia ＊15 All treatment include withdrawl of anti-TNF therapy ＊16 PSL prednisolone ＊17 AZP azathioprine ＊18 MP methylprednisolone ＊19 IVCY intravenous cyclophosphamide 
Table 1. Clinical Characteristics of Reported RA Patients Who Developed PM/DM After Anti-TNF Therapy   
